Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0312 • ACR Convergence 2022
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
Lara Pupim¹, Gerd Burmester², Fang Fang¹, Alan Kivitz³, Moses Njenga¹, Costantino Pitzalis⁴, Jay Chatfield¹, Anastassia Papandrikopoulou¹, Manoj Samant¹, Steve Schmitz¹, Madeline Spiers¹, Eben Tessari¹, John Ziemniak¹ and John F. Paolini⁵, ¹Kiniksa, Lexington, MA, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Queen Mary University of London, London, United Kingdom, ⁵Kiniksa Pharmaceuticals, Lexington, MA
Background/Purpose: An unmet need remains in patients with failure and/or inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARD-IR) and/or Janus kinase inhibitors (JAKi-IR). The…
Abstract Number: 0705 • ACR Convergence 2022
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
Laura Boekel¹, Yaëlle Besten¹, Femke Hooijberg¹, Rosa Wartena¹, Maurice Steenhuis², Erik Vogelzang³, Maureen Leeuw¹, Sadaf Atiqi¹, Sander Tas⁴, Willem Lems⁵, Marieke van Ham², Filip Eftimov³, Eileen Stalman³, Luuk Wieske³, Taco Kuijpers³, Alexandre Voskuyl⁶, Ronald van Vollenhoven⁷, Martijn Gerritsen¹, Charlotte Krieckaert¹, Theo Rispens², Maarten Boers⁸, Michael Nurmohamed⁹ and Gertjan Wolbink¹, ¹Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ²Sanquin Research, Amsterdam, Netherlands, ³Amsterdam UMC, location AMC, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location VUMC, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: The Omicron (B.1.1.529) variant of SARS-CoV-2 is associated with substantially lower hospitalization rates compared with previous variants of SARS-CoV-2 (i.e., Wildtype, Alpha [B.1.1.7] and…
Abstract Number: 0837 • ACR Convergence 2022
Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
Chris Ching¹, Erica Mulcaire-Jones², Andrew Shaffer¹, Jeremy Gililland¹, Michael Battistone³ and Dorota Lebiedz-Odrobina¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Healthcare, Salt Lake City, UT, ³Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Rate of prosthetic joint infection (PJI) after total joint arthroplasty (TJA) is higher in patients with rheumatic conditions than in patients with OA. Our…
Abstract Number: 0934 • ACR Convergence 2022
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jinhyun Kim⁴, Eun Bong Lee¹ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ³Ajou University School of Medicine, Suwon, Republic of Korea, ⁴Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
Abstract Number: 1339 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Matthew Wong-Pack¹, Elliot Hepworth², Mohammad Movahedi³, Bindee Kuriya¹, Janet Pope⁴, Edward Keystone⁵, Carter Thorne⁶, VANDANA AHLUWALIA⁷, Angela Cesta⁸, Carol Mously⁸, Claire Bombardier¹, Arthur Lau⁹ and Sibel Aydin¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷William Osler Health System, Brampton, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada
Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in…
Abstract Number: 1654 • ACR Convergence 2022
Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
Jacquelyn Nestor¹, Christian Mancini¹, Baijun Zhou¹, Yuqing Zhang², Karen Costenbader³, Hyon Choi⁴ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is the backbone of SLE therapy, due to its benefits on increasing survival and decreasing lupus flares. In 2011, ophthalmology guidelines recommended…
Abstract Number: 1984 • ACR Convergence 2022
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
jacques-eric gottenberg¹, Nadir Mammar², Meriem Kessouri², Jeremie RUDANT², nada Assi³, Fanny raguideau³ and julien kirchgesner⁴, ¹Strasbourg University Hospital, Strasbourg, France, ²Pfizer, Paris, France, ³HEVA, Lyon, France, ⁴AP-HP, Paris, France
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…
Abstract Number: 2194 • ACR Convergence 2022
Is Vaccination Against Covid-19 Associated with Autoimmune Rheumatic Disease Flare? Self-controlled Case Series Analysis Using Data from the Clinical Practice Research Datalink (Aurum)
Georgina Nakafero¹, Matthew J. Grainge¹, Tim Card¹, Christian Mallen², Jonathan S. Nguyen van Tam¹, Hywel C. Williams¹ and Abhishek Abhishek¹, ¹University of Nottingham, Nottingham, United Kingdom, ²Keele University, Keele, United Kingdom
Background/Purpose: It is unclear whether autoimmune rheumatic disease (AIRD) flares are associated with the recent prior Covid-19 vaccination, and whether the association was influenced by…
Abstract Number: 0264 • ACR Convergence 2022
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Kent Kwas Huston¹, Christopher Adams², Simon Helfgott³, Jasvinder singh⁴, Nehad Soloman⁵, Dan Persons⁶, Scott Milligan⁶ and Colin Edgerton², ¹Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ²Articularis Healthcare, Sullivans Island, SC, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Trio Health, Louisville, CO
Background/Purpose: The development, exacerbation, or unimprovement of clinical conditions during DMARD treatment may lead patients to abandon treatment before the necessary time has elapsed for…
Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Alba Herrero-Morant¹, Jon Zubiaur-Zamacola², Adrián Margarida-De Castro², Raquel Pérez-Barquín², Miguel Ángel González-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…
Abstract Number: 0708 • ACR Convergence 2022
The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and acute care utilization among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods:…
Abstract Number: 0897 • ACR Convergence 2022
Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
Gregory McDermott¹, Kumar Dahal¹, Su-Jin Moon², Thany Seyok¹, Dana Weisenfeld¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Despite the efficacy of modern biologic and small molecule medications, a significant proportion of RA patients have inadequate response to multiple therapies. These patients…
Abstract Number: 0945 • ACR Convergence 2022
Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry
John Bridges¹, Jing Li², Melissa Mannion³, Gabriela Schmajuk⁴ and Jasvinder singh³, ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients with juvenile idiopathic arthritis (JIA) have disease onset during childhood and often require anti-rheumatic medication through their reproductive years. Contraception use in reproductive-age…
Abstract Number: 1342 • ACR Convergence 2022
Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients
Reid Weisberg¹, Brett Capel¹, Annabelle Guo¹, Komal Patel¹, Rashmi Arora², Swathi Reddy³ and Una Makris⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Dallas VA Medical Center / University of Texas Southwestern Medical Center, Dallas, TX, ³Dallas VA Medical Center / University of Texas Southwestern Medical Center, Colleyville, TX, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: In September 2021, the FDA updated its boxed warnings for Janus Kinase (JAK) inhibitors to include increased risk of major adverse cardiac events (MACE)…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].